Glaukos Corporation (NYSE:GKOS) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On May 3, 2017, Glaukos Corporation issued a press release
announcing its financial results for the first quarter ended
March 31, 2017. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the
accompanying Exhibit 99.1 shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
under the Exchange Act or the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in
such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

About Glaukos Corporation (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Glaukos Corporation (NYSE:GKOS) Recent Trading Information

Glaukos Corporation (NYSE:GKOS) closed its last trading session down -0.57 at 47.62 with 372,823 shares trading hands.